[Las Vegas, United States] DelveInsight, a leader in healthcare research firm, has recently published an in-depth report on Tirzepatide (Eli Lilly and Company) providing insights into the drug market landscape and market forecast of Tirzepatide upto 2032. The report, titled "Tirzepatide, Market Size, Forecast, and Emerging Insight – 2034" is now available for review and analysis.
Are you interested in finding out the projected market size of Tirzepatide in 2032? Tirzepatide Market Forecast
https://www.delveinsight.com/report-store/tirzepatide-emerging-drug-insight-and-market-forecast
Key Factors Driving Tirzepatide Growth
1. Market Share Gains and New Patient Starts
-
Tirzepatide is quickly gaining market share in type 2 diabetes and obesity management, establishing itself as one of the most successful recent drug launches.
-
A notable increase in new patient initiations is driving robust prescription growth, supported by strong demand from both diabetes and obesity specialists.
-
Eli Lilly’s proactive commercial approach, extensive physician education programs, and direct-to-consumer campaigns are accelerating widespread adoption across treatment areas.
2. Expansion Across Key Indications
-
Type 2 Diabetes (Mounjaro): Authorized as a once-weekly injectable dual GLP-1/GIP agonist, offering superior HbA1c reduction and weight loss versus current GLP-1 treatments.
-
Obesity/Weight Management (Zepbound): Newly approved for chronic weight management, demonstrating remarkable weight-loss outcomes that are fueling rapid adoption.
-
Cardiovascular Risk Reduction: Current studies are assessing tirzepatide’s impact on cardiovascular outcomes, representing a key potential driver for market growth.
-
Pipeline Developments: Ongoing research in NASH, obstructive sleep apnea, and HFpEF indicates promising potential for expanding future therapeutic applications.
The Tirzepatide Market Report offers projected sales forecasts for Tirzepatide for indications until 2032, categorized across the 7MM i.e. United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan. The report also provides extensive coverage and a competitive landscape analysis of competitors and marketed products indication. It also covers analyst views along with market drivers and barriers.
Eli Lilly and Companies Tirzepatide is serving as a beacon of hope for the patients suffering from Type 2 Diabetes and Obesity.
Tirzepatide Recent Developments
-
In September 2025, Eli Lilly and Company released detailed findings from SURPASS-PEDS, the first Phase III trial assessing the safety and efficacy of MOUNJARO (tirzepatide), a dual GIP/GLP-1 receptor agonist, in children and adolescents aged 10 to under 18 with type 2 diabetes inadequately managed with metformin, basal insulin, or both. At 30 weeks, MOUNJARO achieved the primary and all key secondary endpoints, showing superior reductions in A1C and body mass index (BMI) versus placebo. These results were presented at the 2025 EASD Annual Meeting and published in The Lancet.
-
In July 2025, Eli Lilly and Company reported topline results from SURPASS-CVOT, a pioneering Phase III cardiovascular outcomes trial directly comparing two incretin therapies in adults with type 2 diabetes and established atherosclerotic cardiovascular disease. MOUNJARO (tirzepatide), a dual GIP/GLP-1 receptor agonist, was evaluated against Trulicity (dulaglutide), a GLP-1 receptor agonist previously shown to provide cardiovascular benefits in the REWIND study. The trial met its primary endpoint, with MOUNJARO demonstrating non-inferiority in the rate of major adverse cardiovascular events (MACE-3), including cardiovascular death, heart attack, or stroke, compared to Trulicity.
What is Tirzepatide Prescribed for?
Tirzepatide is a prescription medication primarily indicated for the treatment of type 2 diabetes mellitus to improve glycemic control in adults. It functions as a dual GIP and GLP-1 receptor agonist, enhancing insulin secretion, reducing glucagon levels, and promoting weight loss. Beyond diabetes, tirzepatide is increasingly used off-label for chronic weight management and obesity, supported by clinical trials showing significant reductions in body weight. It is typically prescribed alongside lifestyle interventions, such as a reduced-calorie diet and increased physical activity, and may be considered for patients who require additional metabolic benefits beyond standard diabetes therapies.
The report extensively covers the details and developments related to Tirzepatide, capturing important highlights on developmental pipeline, regulatory status and special designations of Tirzepatide, route of administration, safety and efficacy details.
Tirzepatide Market Assessment
This report provides a detailed market assessment of Tirzepatide for Type 2 Diabetes and Obesity in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides forecasted sales data from 2026 to 2032.
Tirzepatide Clinical Assessment
The report provides the clinical trials information of Tirzepatide for Type 2 Diabetes and Obesity covering trial interventions, trial conditions, trial status, start and completion dates. Report also includes important insights on regulatory milestones and other developmental activities related.
Do you know your drug’s competitive positioning against Tirzepatide? Tirzepatide Drugs Insights
Tirzepatide Competitive Landscape
The report offers insights into the key players and companies actively engaged in the development of the specified indication. It provides valuable information regarding the competitive positioning of the Tirzepatide.
Tirzepatide Market Size in the US
A dedicated section of the report focuses on the expected market size of Tirzepatide for the United States. DelveInsight's analysis includes market trends, growth projections, and key factors influencing the market dynamics, offering a comprehensive perspective for stakeholders.
Key Highlights of Tirzepatide:
-
The report contains forecasted sales of Tirzepatide for indication till 2032.
-
Comprehensive coverage of the late-stage emerging therapies for Type 2 Diabetes and Obesity.
-
The report also features the qualitative and quantitative analysis with analysts as well as KOL views for Tirzepatide in Type 2 Diabetes and Obesity.
Stay ahead in competition by leveraging insights on Tirzepatide market Report: Download Tirzepatide Market Report
Why you should buy Tirzepatide Market Report:
-
The report provides future market assessments for Tirzepatide for Type 2 Diabetes and Obesity in the 7 Major Markets, Advance qualitative analysis like SWOT, expert analysts’ views, detailed overview of market competitors, and short analysis of other emerging therapies in Ulcerative Colitis.
-
Leading Tirzepatide for Type 2 Diabetes and Obesity forecasted market data will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the Tirzepatide
-
Discover the competitive landscape of Tirzepatide through 7MM
-
Get a Thorough Analysis of the Tirzepatide Development pipeline, Safety & Efficacy of the Tirzepatide, and ROA
-
Thorough Tirzepatide market forecast will help understand how drug is competing with other emerging Tirzepatide
-
Get analysis of the Tirzepatide clinical trial advancements and the detailed clinical assessment, regulatory and commercial assessment
-
Drug Market forecasts are calculated after taking into consideration KOL viewpoints
Related Reports By DelveInsight:
Type 2 Diabetes Pipeline
DelveInsight’s, “Type 2 Diabetes Pipeline Insight, 2025” report provides comprehensive insights about 75+ companies and 80+ pipeline drugs in the Type 2 Diabetes pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Obesity Pipeline
DelveInsight’s, “Obesity Pipeline Insight, 2025” report provides comprehensive insights about 80+ companies and 100+ pipeline drugs in the Obesity pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products.
It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States
Website: https://www.delveinsight.com/
